AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Lucid Diagnostics, a cancer prevention medical diagnostics company, announced participation in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. CFO Dennis McGrath will be available for one-on-one meetings with investors. The company's EsoGuard Esophageal DNA Test is designed to detect esophageal precancer and cancer in patients with gastroesophageal reflux disease (GERD).
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet